The Core provides the mechanism for integrating and coordinating the interdisciplinary approaches to drug abuse research at Virginia Commonwealth University (VCU). It provides shared resources and serves to Facilitate communication among all investigators in the Center. Moreover, the Core is available to all drug abuse researchers at VCU. It serves as a mechanism for fostering interactions among the participants in the Center and those who are supported by other NIDA grants. The Core consists of four components. The Administrative Component is responsible for scheduling drug abuse seminars, attending to travel for invited speakers, organizing regular meetings for participating faculty, coordinating scientific exchange, distribution of drugs to collaborators, and fostering training. The Mass Spectrometry Component provides qualitative and quantitative sample analysis that is essential for many of the drug abuse research projects at the University. The Small Grants Program will support two VCU faculty members yearly. The goals are to fund promising young investigators who demonstrate potential for independent research, to attract senior scientists from other fields into drug abuse research, and to foster new collaborations. Past awardees have subsequently been very successful in obtaining their own individual funding as a result of the Small Grants Program. The Mouse 'Knock-out Facility'provides genetically modified mice to investigators working in cannabinoid, opioid, and nicotine areas. The facility will allow sufficient breeding so that adequate numbers of animals will be available. A major advantage of a Center Core is that it provides shared resources that are more economical and that are sometimes not available unless they are funded by this type mechanism. Of course, the Core also affords the opportunity for researchers from many different disciplines to become familiar with areas of research that will complement their own endeavors. It is also through the Core that we are able to be a national resource.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005274-23
Application #
8286318
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
23
Fiscal Year
2011
Total Cost
$320,095
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Bagdas, Deniz; Alkhlaif, Yasmin; Jackson, Asti et al. (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 138:72-79
Jackson, Kia J; Muldoon, Pretal P; Walters, Carrie et al. (2016) Neuronal calcium/calmodulin-dependent protein kinase II mediates nicotine reward in the conditioned place preference test in mice. Behav Pharmacol 27:50-6
Nass, Sara R; Long, Jonathan Z; Schlosburg, Joel E et al. (2015) Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol 10:364-70
Muldoon, P P; Chen, J; Harenza, J L et al. (2015) Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Br J Pharmacol 172:869-82
Poklis, Justin L; Devers, Kelly G; Arbefeville, Elise F et al. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:e14-20
Poklis, Justin L; Nanco, Carol R; Troendle, Michelle M et al. (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764-9
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Bagdas, Deniz; Muldoon, Pretal P; Zhu, Andy Z X et al. (2014) Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 85:67-72
Wolf, Carl E; Goldstein, Ashley; Poklis, Justin L et al. (2014) Evaluation of an enzyme immunoassay for the detection of methadone metabolite EDDP [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine] in urine. J Clin Lab Anal 28:136-40
Kinsey, Steven G; Wise, Laura E; Ramesh, Divya et al. (2013) Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345:492-501

Showing the most recent 10 out of 106 publications